Skip to main content

Sars-cov-2 Mrna (tozinameran) Vaccine Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 16, 2025.

Applies to sars-cov-2 mrna (tozinameran) vaccine: intramuscular suspension.

Local adverse events

Nervous system

Bell's palsy occurred in 4 patients in the treatment group versus 2 patients in the placebo group. Onset of facial paralysis occurred on day 37 after dose 1 (patient only received one dose), and days 3, 9, and 48 after dose 2 in the treatment group; onset of facial paralysis was day 30 and 102 in the placebo group. Currently available information is insufficient to determine a causal relationship with the vaccine.[Ref]

Other

Musculoskeletal

Gastrointestinal

Hypersensitivity

Cardiovascular

Dermatologic

Hematologic

Metabolic

References

1. "Product Information. Pfizer-BioNTech COVID-19 Vaccine PF (SARS-CoV-2 (COVID-19) mRNA BNT-162b2 vaccine)." Pfizer Inc., Madison, NJ.

2. (2022) "Product Information. Pfizer-BioNTech COVID-19 Vaccine PF (SARS-CoV-2 mRNA (tozinameran) vaccine)." Pfizer Inc.

Frequently asked questions

Further information

Sars-cov-2 mrna (tozinameran) vaccine side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.